IDH1 and cancer: Together, these synthetic lethal strategies expand the therapeutic landscape of mIDH1 cancers, offering rational combinations with IDH inhibitors or alternative therapies when resistance emerges, even as some vulnerabilities persist or evolve after 2-HG suppression.